{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:13:31Z","timestamp":1774743211562,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"publisher","award":["2018A030310299"],"award-info":[{"award-number":["2018A030310299"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s13577-020-00367-1","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T19:02:22Z","timestamp":1588014142000},"page":"610-618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["MicroRNA-153-3p enhances the sensitivity of chronic myeloid leukemia cells to imatinib by inhibiting B-cell lymphoma-2-mediated autophagy"],"prefix":"10.1007","volume":"33","author":[{"given":"Yu-Ling","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Ming","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Hua","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Yuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,27]]},"reference":[{"key":"367_CR1","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","volume":"124","author":"S Branford","year":"2014","unstructured":"Branford S, Yeung DT, Parker WT, et al. Prognosis for patients with CML and %3e\u200910% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 2014;124:511\u20138.","journal-title":"Blood"},{"key":"367_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/00001622-200101000-00002","volume":"13","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, O'Brien SG, Jorge C, Jerald R. Chronic myelogenous leukemia. Curr Opin Oncol. 2001;13:3.","journal-title":"Curr Opin Oncol"},{"key":"367_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ruibao","year":"2005","unstructured":"Ruibao R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5:172\u201383.","journal-title":"Nat Rev Cancer"},{"key":"367_CR4","first-page":"671702","volume":"2012","author":"GND Moraes","year":"2012","unstructured":"Moraes GND, Souza PS, Costas FCDF, Vasconcelos FC, Maia RC. The Interface between BCR-ABL-dependent and -independent resistance signaling pathways in chronic myeloid leukemia. Leukemia Res Treatment. 2012;2012:671702.","journal-title":"Leukemia Res Treatment"},{"key":"367_CR5","doi-asserted-by":"publisher","first-page":"12369","DOI":"10.1002\/jcp.28058","volume":"234","author":"H Mollaei","year":"2019","unstructured":"Mollaei H, Safaralizadeh R, Rostami Z. MicroRNA replacement therapy in cancer. J Cell Physiol. 2019;234:12369\u201384.","journal-title":"J Cell Physiol"},{"key":"367_CR6","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","volume":"53","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615\u201327.","journal-title":"Annu Rev Med"},{"key":"367_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3892\/or.2015.3952","volume":"34","author":"J Zhou","year":"2015","unstructured":"Zhou J, Xie M, Shi Y, et al. MicroRNA-153 functions as a tumor suppressor by targeting SET7 and ZEB2 in ovarian cancer cells. Oncol Rep. 2015;34:111.","journal-title":"Oncol Rep"},{"key":"367_CR8","doi-asserted-by":"publisher","first-page":"e3083","DOI":"10.1002\/jgm.3083","volume":"21","author":"Z Cui","year":"2019","unstructured":"Cui Z, Luo Z, Lin Z, et al. Long non-coding RNA TTN-AS1 facilitates tumorigenesis of papillary thyroid cancer through modulating the miR-153-3p\/ZNRF2 axis. J Gene Med. 2019;21:e3083.","journal-title":"J Gene Med."},{"key":"367_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bbrc.2018.05.114","volume":"502","author":"W Luan","year":"2018","unstructured":"Luan W, Shi Y, Zhou Z, et al. circRNA_0084043 promote malignant melanoma progression via miR-153-3p\/Snail axis. Biochem Biophys Res Commun. 2018;502:22\u20139.","journal-title":"Biochem Biophys Res Commun."},{"key":"367_CR10","doi-asserted-by":"publisher","first-page":"153303381985299","DOI":"10.1177\/1533033819852990","volume":"18","author":"J Jiang","year":"2019","unstructured":"Jiang J, Liu Y, Zhao Y, Tian F, Wang G. miR-153-3p suppresses inhibitor of growth protein 2 expression to function as tumor suppressor in acute lymphoblastic leukemia. Technol Cancer Res Treatment. 2019;18:1533033819852990.","journal-title":"Technol Cancer Res Treatment"},{"key":"367_CR11","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1126\/science.1099993","volume":"306","author":"T Shintani","year":"2004","unstructured":"Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science. 2004;306:990\u20135.","journal-title":"Science"},{"key":"367_CR12","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.4155\/fmc.15.88","volume":"7","author":"K Ankit","year":"2015","unstructured":"Ankit K, Umesh Kumar S, Anurag C. Targeting autophagy to overcome drug resistance in cancer therapy. Future Med Chem. 2015;7:1535\u201342.","journal-title":"Future Med Chem"},{"key":"367_CR13","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/ncb1634","volume":"9","author":"Y Takahashi","year":"2007","unstructured":"Takahashi Y, Coppola D, Matsushita N, et al. Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol. 2007;9:1142\u201351.","journal-title":"Nat Cell Biol."},{"key":"367_CR14","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1158\/1538-7445.AM2017-3310","volume":"77","author":"J Zhu","year":"2017","unstructured":"Zhu J, Li Y, Huang C, Huang H. Abstract 3310: Atg7 overexpression promotes bladder cancer invasion via autophagic removal of AUF1 protein and subsequently increased RhoGDI2 mRNA stability in vitro and in vivo. Can Res. 2017;77:3310\u2013410.","journal-title":"Can Res"},{"issue":"1","key":"367_CR15","doi-asserted-by":"publisher","first-page":"e1030539","DOI":"10.1080\/23723556.2015.1030539","volume":"3","author":"RA Rohatgi","year":"2016","unstructured":"Rohatgi RA, Shaw LM. An autophagy-independent function for Beclin 1 in cancer. Mol Cell Oncol. 2016;3(1):e1030539.","journal-title":"Mol Cell Oncol."},{"key":"367_CR16","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.4161\/cc.10.11.15673","volume":"10","author":"W Alexander Scarth","year":"2011","unstructured":"Alexander Scarth W, Monika M, Anna KS. Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia. Cell Cycle. 2011;10:1719\u201325.","journal-title":"Cell Cycle"},{"key":"367_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/ajh.21914","volume":"86","author":"LC Crowley","year":"2011","unstructured":"Crowley LC, Elzinga BM, O'Sullivan GC, Mckenna SL. Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment. Am J Hematol. 2011;86:38\u201347.","journal-title":"Am J Hematol"},{"key":"367_CR18","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1172\/JCI35660","volume":"119","author":"B Cristian","year":"2009","unstructured":"Cristian B, Maria Rosa L, Ashley H, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Investig. 2009;119:1109\u201323.","journal-title":"J Clin Investig"},{"key":"367_CR19","doi-asserted-by":"publisher","first-page":"600","DOI":"10.4161\/auto.6260","volume":"4","author":"L Beth","year":"2008","unstructured":"Beth L, Sangita S, Guido K. Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy. 2008;4:600\u20136.","journal-title":"Autophagy"},{"key":"367_CR20","doi-asserted-by":"publisher","first-page":"R940","DOI":"10.1186\/bcr1323","volume":"7","author":"E Manabu","year":"2005","unstructured":"Manabu E, Ryungsa K, Kazuaki T, et al. Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res. 2005;7:R940\u2013R952952.","journal-title":"Breast Cancer Res"},{"key":"367_CR21","doi-asserted-by":"publisher","first-page":"e0156260","DOI":"10.1371\/journal.pone.0156260","volume":"11","author":"TY Lin","year":"2016","unstructured":"Lin TY, Chen KC, Liu HJ, et al. MicroRNA-1301-mediated RanGAP1 downregulation induces BCR-ABL nuclear entrapment to enhance imatinib efficacy in chronic myeloid leukemia cells. PLoS ONE. 2016;11:e0156260.","journal-title":"PLoS ONE"},{"key":"367_CR22","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2147\/DDDT.S191303","volume":"13","author":"S Flis","year":"2019","unstructured":"Flis S, Chojnacki T. Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities. Drug Des Devel Ther. 2019;13:825\u201343.","journal-title":"Drug Des Devel Ther"},{"key":"367_CR23","doi-asserted-by":"publisher","first-page":"12460","DOI":"10.1038\/srep12460","volume":"5","author":"X Zhu","year":"2015","unstructured":"Zhu X, Lin Z, Du J, et al. MicroRNA-320a acts as a tumor suppressor by targeting BCR\/ABL oncogene in chronic myeloid leukemia. Sci Rep. 2015;5:12460.","journal-title":"Sci Rep"},{"key":"367_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-1-59745-157-4_4","volume":"445","author":"I Tanida","year":"2008","unstructured":"Tanida I, Ueno T, Kominami E. LC3 and autophagy. Methods Mol Biol. 2008;445:77\u201388.","journal-title":"Methods Mol Biol"},{"key":"367_CR25","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.clml.2013.03.018","volume":"13","author":"EJ Jabbour","year":"2013","unstructured":"Jabbour EJ, Cortes JE, Kantarjian HM. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leukemia. 2013;13:515\u201329.","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"367_CR26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12967-016-1012-8","volume":"14","author":"Y Lu","year":"2016","unstructured":"Lu Y, Liu LL, Liu SS, et al. Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells. J Transl Med. 2016;14:270.","journal-title":"J Transl Med"},{"key":"367_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3324\/haematol.10279","volume":"92","author":"U Testa","year":"2007","unstructured":"Testa U, Riccioni R. Deregulation of apoptosis in acute myeloid leukemia. Haematologica. 2007;92:81.","journal-title":"Haematologica"},{"key":"367_CR28","first-page":"4127","volume":"14","author":"J Colin","year":"2008","unstructured":"Colin J, Gaumer S, Guenal I, Mignotte B. Mitochondria, Bcl-2 family proteins and apoptosomes: of worms, flies and men. Front Biosci. 2008;14:4127\u201337.","journal-title":"Front Biosci"},{"key":"367_CR29","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1021\/acschembio.8b00421","volume":"13","author":"WC Chiang","year":"2018","unstructured":"Chiang W-C, Wei Y, Kuo Y-C, et al. High-throughput screens to identify autophagy inducers that function by disrupting Beclin 1\/Bcl-2 binding. ACS Chem Biol. 2018;13:2247\u201360","journal-title":"ACS Chem Biol."},{"key":"367_CR30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40659-018-0203-6","volume":"51","author":"D Sun","year":"2018","unstructured":"Sun D, Mu Y, Piao H. MicroRNA-153-3p enhances cell radiosensitivity by targeting BCL2 in human glioma. Biol Res. 2018;51:56.","journal-title":"Biol Res"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-020-00367-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-020-00367-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-020-00367-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T11:02:18Z","timestamp":1666436538000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-020-00367-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,27]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["367"],"URL":"https:\/\/doi.org\/10.1007\/s13577-020-00367-1","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,27]]},"assertion":[{"value":"29 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All human blood samples investigated in this study were in accordance with the ethical standards of the Ethics Committee of The Third Affiliated Hospital of Guangzhou Medical University, and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual sample donor included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the publication of this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}